MOBICOX TABLET

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

MELOXICAM

זמין מ:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

קוד ATC:

M01AC06

INN (שם בינלאומי):

MELOXICAM

כמות:

15MG

טופס פרצבטיות:

TABLET

הרכב:

MELOXICAM 15MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

100

סוג מרשם:

Prescription

איזור תרפויטי:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

leaflet_short:

Active ingredient group (AIG) number: 0131676004; AHFS:

מצב אישור:

CANCELLED POST MARKET

תאריך אישור:

2018-08-17

מאפייני מוצר

_MOBICOX Product Monograph_
_Page 1 of 47_
PRODUCT MONOGRAPH
Pr
MOBICOX
®
meloxicam
Tablet 7.5 & 15.0 mg
Non-Steroidal Anti-Inflammatory Drug (NSAID)
Boehringer Ingelheim (Canada) Ltd.
5180 South Service Road
Burlington, Ontario L7L 5H4
DATE OF REVISION:
November 6, 2014
SUBMISSION CONTROL NO: 176777
BICL-CCDS#0203-11
_MOBICOX Product Monograph_
_Page 2 of 47_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE
REACTIONS..................................................................................................15
DRUG INTERACTIONS
..................................................................................................21
DOSAGE AND ADMINISTRATION
..............................................................................28
ACTION AND CLINICAL PHARMACOLOGY
............................................................30
STORAGE AND STABILITY
..........................................................................................35
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................35
PART II: SCIENTIFIC INFORMATION
...............................................................................36
PHARMACEUTICAL
INFORMATION..........................................................................36
CLINICAL TRIALS
..........................................................................................................36
DETAILED PHARMACOLOGY
.....................................................................................39
TOXICOLOGY
.......................